These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 1816187)

  • 1. Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion.
    Mouton JW; Michel MF
    J Antimicrob Chemother; 1991 Dec; 28(6):911-8. PubMed ID: 1816187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.
    Mouton JW; Horrevorts AM; Mulder PG; Prens EP; Michel MF
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2307-11. PubMed ID: 2088186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
    Krueger WA; Bulitta J; Kinzig-Schippers M; Landersdorfer C; Holzgrabe U; Naber KG; Drusano GL; Sörgel F
    Antimicrob Agents Chemother; 2005 May; 49(5):1881-9. PubMed ID: 15855510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of meropenem, administered at 500 milligrams every 8 hours, in plasma and cantharidin-induced skin blister fluid.
    Maglio D; Teng R; Thyrum PT; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2003 May; 47(5):1771-3. PubMed ID: 12709358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis.
    Kuti JL; Nightingale CH; Knauft RF; Nicolau DP
    Clin Ther; 2004 Apr; 26(4):493-501. PubMed ID: 15189746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion versus intermittent administration of meropenem in critically ill patients.
    Thalhammer F; Traunmüller F; El Menyawi I; Frass M; Hollenstein UM; Locker GJ; Stoiser B; Staudinger T; Thalhammer-Scherrer R; Burgmann H
    J Antimicrob Chemother; 1999 Apr; 43(4):523-7. PubMed ID: 10350382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics of ceftriaxone in serum, skin blister and thread fluid.
    Kalager T; Digranes A; Bergan T; Solberg CO
    J Antimicrob Chemother; 1984 May; 13(5):479-85. PubMed ID: 6330020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.
    Sun HK; Ong CT; Umer A; Harper D; Troy S; Nightingale CH; Nicolau DP
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1629-32. PubMed ID: 15793157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and tissue penetration of Timentin: a simultaneous study of serum, urine, lymph, suction blister and subcutaneous thread fluid.
    Walstad RA; Hellum KB; Thurmann-Nielsen E; Dale LG
    J Antimicrob Chemother; 1986 May; 17 Suppl C():71-80. PubMed ID: 3722049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.
    Jaruratanasirikul S; Sriwiriyajan S
    J Antimicrob Chemother; 2003 Sep; 52(3):518-21. PubMed ID: 12917242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
    Kelly HC; Hutchison M; Haworth SJ
    J Antimicrob Chemother; 1995 Jul; 36 Suppl A():35-41. PubMed ID: 8543497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery.
    Wittau M; Scheele J; Kurlbaum M; Brockschmidt C; Wolf AM; Hemper E; Henne-Bruns D; Bulitta JB
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6241-7. PubMed ID: 26248353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacokinetics of meropenem administered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration].
    Bo SN; Li HL; Zhu X; Yao GQ; Hu YF; Zhai SD; Lu W; Wang SY; Xu YZ; He B
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2012 Mar; 24(3):145-8. PubMed ID: 22401158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefodizime penetration into skin suction blister fluid following a single intravenous dose.
    Schäfer-Korting M; Korting HC; Maass L; Klesel N; Grigoleit HG; Mutschler E
    Eur J Clin Pharmacol; 1986; 30(3):295-8. PubMed ID: 3732363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of continuous-infusion meropenem for the treatment of Serratia marcescens ventriculitis in a pediatric patient.
    Cies JJ; Moore WS; Calaman S; Brown M; Narayan P; Parker J; Chopra A
    Pharmacotherapy; 2015 Apr; 35(4):e32-6. PubMed ID: 25884534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and tissue penetration of intravenously administered CGP 31608.
    Wise R; Webberley JM; Andrews JM; Ashby JP
    J Antimicrob Chemother; 1988 Jan; 21(1):85-91. PubMed ID: 3356625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofloxacin: serum and skin blister fluid pharmacokinetics in the fasting and non-fasting state.
    Kalager T; Digranes A; Bergan T; Rolstad T
    J Antimicrob Chemother; 1986 Jun; 17(6):795-800. PubMed ID: 3460984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.
    Dandekar PK; Maglio D; Sutherland CA; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2003 Aug; 23(8):988-91. PubMed ID: 12921245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.